Timolol prevents cell stress

Article

Glaucoma medication timolol exerts a direct antioxidant effect, protecting human endothelial cells from oxidative stress.

Glaucoma medication timolol exerts a direct antioxidant effect, protecting human endothelial cells from oxidative stress, according to a paper printed online ahead of publication in Eye.

Segio Sacca and colleagues from the University of Genoa and St Martino Hospital, Genoa, Italy induced oxidative stress in cultures of human endothelial cells using iron/ascorbate with or without timolol pre-treatment. Parameters for analysis included cell viability (neutral red uptake and tetrazolium salt tests), lipid peroxidation (thiobarbituric reactive substances) and occurrence of molecular oxidative damage to DNA (8-hydroxy-2'-deoxyguanosine).

Researchers founds that oxidative stress caused a 1.8-fold decrease in cell viability, a 3.0-fold increase in lipid peroxidation and a 64-fold increase in oxidative damage to DNA. In the presence of timolol, oxidative stress did not modify cell viability, whereas lipid peroxidation was increased 1.3-fold and DNA oxidative damage 3.6-fold.

The researchers concluded that timolol does exert a direct antioxidant effect that protects human endothelial cells from oxidative stress.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.